Dr. Ragupathy “Madi” Madiyalakan, Ph.D., CEO
Dr. Madiyalakan is the CEO and director of OncoQuest since its inception and the CEO of Quest PharmaTech since August, 2006; and Director since July, 2004. He was one of the founders of SonoLight Pharmaceuticals Corp. (served as its CEO and Director), CanBiocin Inc. (served as President, CEO and Director) and AltaRex Corp. (served as Vice-President, Planning and Chief Scientific Officer). Between 1987 and 1995 Dr. Madiyalakan served in various senior positions at Biomira Inc. Dr. Madiyalakan holds a Masters (Chemistry) and Ph.D. (Biochemistry) and a Certificate in Management Development. In addition, he has over 35 years of academic and industrial research experience on an international basis. He has published extensively and been an inventor of a number of patents.
Bin Huang, Ph.D., MBA
Dr. Huang is currently the President and CEO of Emerald Health Therapeutics Inc., a life sciences company listed on the TSX. She was President of Renaissance Yeast Inc. from 2013 to 2014, President and CEO of WEX Pharmaceuticals Inc. between 2007 and 2012, Chief Executive Officer of GeneHarbor Technologies Limited between 2004 and 2006 and President and CEO of Cytovax Biotechnologies Inc. between 1999 and 2004. Prior to Cytovax, Dr. Huang was Vice President of Business Development for Monsanto Canada. Dr. Huang has also worked as a biotechnology analyst and was a partner with GMP Securities, a Toronto investment dealer. Dr. Huang received her PhD in Cell Biology from the University of East Anglia, UK, and her MBA from the University of Toronto.
Shawn Lu, CIM, MFin
Mr. Lu is currently the chief financial officer of Hepalink USA Inc. and has served in this capacity since 2014. Prior to joining Hepalink USA, Mr. Lu was employed as the Area Manager for BMO Bank of Montreal in the central Greater Toronto area. From 2005 to 2013, Mr. Lu worked with the TD Bank as a Residential Mortgage Manager in North York, Toronto. From 2001 to 2005, Mr. Lu worked as a senior financial advisor for TD Bank in Toronto. From 1999 to 2000, Mr. Lu was employed with ShenZhen Hepalink Biopharmaceutical Co., Ltd as the CFO and VP of Corporate Finance. From 1998 to 1999, Mr. Lu was employed as the VP of Investment and Corporate Finance with ShenZhen FuTianXin Investment Co., Ltd. From 1992 to 1998, Mr. Lu worked as the General Manager, Corporate finance department, and Manager, Investment and Finance department for China Merchant Shekou Port Co. Ltd. (a ShenZhen Stock Exchange listed company). Mr. Lu has extensive experience in the areas of corporate finance, capital markets and investment financing. Mr. Lu has a Canadian Investment Manager (CIM, Canada) designation and also a Master of Finance Management from Queens University, School of Business, Kingston, Ontario. Mr. Lu also holds a Certified Accountant and Certified Corporate Economist designation in China and has a Master of Corporate Economics and Business Administration from ZhongNan University, Wuhan, China.
Mr. Paul Van Damme, C.P.A.
Mr. Van Damme is currently the CFO for Bradmer Pharmaceuticals, Inc. and for the Structural Genomics Consortium (SGC). He has served in senior financial roles for a number of public companies in both the United States and Canada. He held a number of increasingly responsible positions while at Canada Systems Group from 1983 to 1991, including a line management role, culminating in his appointment as CFO in 1988. In 1991, Mr. Van Damme joined Laidlaw Inc. and helped implement their expansion into Europe. After a period as CFO of a start-up wireless telecommunications company, he joined a private biotech company and helped raise venture financing to expand their product portfolio. In 1997, Mr. Van Damme joined Allelix Pharmaceuticals Inc. and participated in the sale of the company to NPS Pharmaceuticals, Inc. of Salt Lake City in 1999. He also served as CFO of Lorus Therapeutics Inc. and Vasogen Inc. Mr. Van Damme received a B.Comm. from the University of Toronto and an MBA from the Rotman School of Management. He is a Chartered Accountant and articled with PricewaterhouseCoopers where he served as Audit Manager in London, England and Toronto. Mr. Van Damme currently serves as a director of Insception Biosciences Inc.
Mr. Xiangyu Gong, MBA.
Mr. Gong has 30 years working experience in the electronics and biopharmaceutical industries and is currently the Vice President - Process and IT Management for Shenzhen Hepalink Pharmaceutical Co. Ltd, Shenzhen, China, a pharmaceutical company listed on the ShenZhen Stock Exchange. Mr. Gong worked as the Director of Operations and Planning Manager for Shenzhen Joyside Industrial Co., Ltd from 2007 to 2011 and was Senior Director of Display Technology for Philips Electronics Co., Ltd, Shanghai, from 2001 to 2007. He has a Masters in Business Administration from the China Europe International Business School, China.